CARE protocol

chemotherapy protocol consisting of above cpds; used in treatment of non-Hodgkin's lymphoma

Therapeutics: 1190486
- Drug Therapy: 300623
  - Combination Drug Therapy: 12155
    - Antineoplastic Combined Chemotherapy Protocols: 36
      - CARE protocol: 342
  - Antineoplastic Protocols: 58
    - Antineoplastic Combined Chemotherapy Protocols: 36
      - CARE protocol: 342
- Clinical Protocols
  - Antineoplastic Protocols: 58
    - Antineoplastic Combined Chemotherapy Protocols: 36
      - CARE protocol: 342
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 521
    - Pyrimidine Nucleosides: 50
      - Cytidine: 548
        Cytarabine: 6746
        CARE protocol: 342
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Pteridines: 149
      - Pterins: 156
        Aminopterin: 244
        Methotrexate: 24421
        CARE protocol: 342
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6937
  - Pyrimidine Nucleosides: 50
    - Cytidine: 548
      - Cytarabine: 6746
        CARE protocol: 342
  - Arabinonucleosides: 1
    - Cytarabine: 6746
      - CARE protocol: 342
Organic Chemicals: 140
- Hydrocarbons: 1726
  - Cyclic Hydrocarbons: 96
    - Aromatic Hydrocarbons: 295
      - Polycyclic Aromatic Hydrocarbons: 2081
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        Podophyllotoxin: 567
        Etoposide: 10835
        CARE protocol: 342
Polycyclic Compounds: 7
- Polycyclic Aromatic Hydrocarbons: 2081
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 567
        Etoposide: 10835
        CARE protocol: 342
Carbohydrates: 22516
- Glycosides: 2186
  - Glucosides: 655
    - Etoposide: 10835
      - CARE protocol: 342

Arnaldo Munive-Degregori Selected Research

Arnaldo Munive-Degregori Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure